Current Report Filing (8-k)
December 17 2019 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2019
EIDOS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-38533
|
|
46-3733671
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco, CA 94104
(Address of principal executive offices, including zip code)
(415) 887-1471
(Telephone number, including area code, of agent for service)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
EIDX
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
Appointment of Uma Sinha as Director
On December 11, 2019, the Board of Directors (the Board) of Eidos Therapeutics, Inc. (the Company) appointed Uma Sinha as a
director of the Board, effective December 11, 2019.
Uma Sinha, Ph.D., has served as the Companys Chief Scientific Officer since June
2016. Dr. Sinha has served as the chief scientific officer at BridgeBio Pharma, LLC since April 2016 and also currently serves as the chief scientific officer of other BridgeBio subsidiaries. Prior to that, Dr. Sinha served as
chief scientific officer of Global Blood Therapeutics, Inc. from 2014 to 2015 and as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. from 2010 to 2012 and was the vice
president of translational biology from 2004 to 2010 and had held senior research positions at Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her
B Sc. with honors in chemistry from Presidency College.
There are no arrangements or understandings between Dr. Sinha and any other persons
pursuant to which she was selected as a director of the Company. Dr. Sinha is not a party to any current or proposed transaction with the Company for which disclosure would be required under Item 404(a) of Regulation S-K.
On December 11, 2019, the Board approved an amendment to the Amended and Restated 2018 Stock Option and Incentive Plan (the Plan) to, among
other things, increase the number of shares of common stock reserved for issuance under the Plan by 1,500,000 shares. Such amendment is subject to the approval of the stockholders of the Company at the Companys annual meeting of stockholders
in 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
Eidos Therapeutics, Inc.
|
|
|
|
Date: December 17, 2019
|
|
By:
|
|
/s/ Christine Siu
|
|
|
|
|
Christine Siu
|
|
|
|
|
Chief Financial Officer
|
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2023 to Apr 2024